Is Actemra used to treat severe cases of COVID-19?

What other treatments has Actemra been used for besides rheumatoid arthritis?

Actemra, also known as tocilizumab, is a medication primarily used to treat rheumatoid arthritis and other inflammatory conditions like juvenile idiopathic arthritis [1]. However, researchers have been exploring its potential in treating severe cases of COVID-19.

Has Actemra shown promise in COVID-19 clinical trials?

Yes, several clinical trials have demonstrated the effectiveness of Actemra in reducing inflammation and mortality in patients with severe COVID-19 [2][3]. These trials have involved a combination of treatments, including corticosteroids, antiviral medications, and oxygen therapy. Tocilizumab has been found to improve lung function and reduce the risk of acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 [4].

Why is Actemra thought to be effective against COVID-19?

Actemra acts by blocking the action of interleukin-6 (IL-6), a cytokine that contributes to inflammation in the body. In patients with severe COVID-19, excessive IL-6 production has been linked to the development of severe lung disease and multi-organ failure [5]. By inhibiting IL-6, Actemra may help to reduce inflammation and prevent these complications.

What are the potential benefits and risks of using Actemra to treat COVID-19?

While Actemra has shown promise in COVID-19 clinical trials, it is essential to weigh the potential benefits against the risks. The most significant concern is the increased risk of infections, including fungal and bacterial infections, in patients receiving Actemra [6]. Additionally, the long-term effects of using Actemra to treat COVID-19 are not yet fully understood.

Is Actemra approved for the treatment of COVID-19?

As of my knowledge cutoff date, Actemra is not specifically approved by regulatory agencies, such as the FDA, for the treatment of COVID-19. However, the FDA has granted Emergency Use Authorization (EUA) for Actemra in patients with severe or critical COVID-19 who require oxygen therapy [7].

Citations:

[1] https://www.drugs.com/tocilizumab.html
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841451/
[3] https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771441
[4] https://www.nejm.org/doi/full/10.1056/NEJMoa2028836
[5] https://pubmed.ncbi.nlm.nih.gov/32329929/
[6] https://www.drugs.com/side-effects/tocilizumab.html
[7] https://www.fda.gov/emergency-use-authorization (as of my knowledge cutoff date)